Uncategorized
Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

Hologic Receives Health Canada Authorization to Market SculpSure® Laser for Non-Invasive Body Contouring (Lipolysis) of the Back, Inner and Outer Thighs, and Under the Chin

 

 

 

 

 

Hologic, Inc. (Nasdaq: HOLX) announced today that it has received a medical device license issued by Health Canada to market Cynosure’s advanced non-invasive body contouring product, SculpSure, for treatment of the back, inner and outer thighs, and submental area (under the chin). Unlike other technologies, the SculpSure device uses a laser that raises the temperature of body fat to precisely disrupt and destroy fat cells under the skin to help patients achieve a natural-looking, slimmer appearance. The fat cells are then naturally eliminated by the body over time and do not return.

 

 

Importantly, SculpSure laser body treatments (abdomen, flanks, back, inner and outer thigh) are recommended for patients with a body mass index (BMI) of 30 or lower, while SculpSure laser submental treatments (under the chin) have been proven effective on patients with a BMI up to 43. This is a significant advantage over the brand’s cryolipolysis competitor, which is only approved to treat patients with a BMI up to 30 in the submental area in the US.

 

 

“This authorization is a testament to our commitment to research and meeting the needs of patients,” said Kevin Thornal, Divisional President of Cynosure at Hologic. “As a leader in medical aesthetics, we strive to build on our already robust data to secure new indications that provide exceptional efficacy.”

 

 

The expanded authorizations for back, inner and outer thighs do not require any updates to previously purchased devices. However, the submental treatment requires practitioners to upgrade their SculpSure device and purchase a simple laser attachment, which allows the applicator to fit seamlessly onto the treatment area. Hologic’s Cynosure sales force will begin distribution immediately to interested practitioners.

 

 

Cynosure, a Hologic company, is a leading developer and manufacturer of a broad array of medical aesthetics systems and technologies. The company has an extensive portfolio of more than 20 products across major categories including body contouring, skin revitalization, women’s health and hair removal.

 

 

About Hologic, Inc.   

 

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

 

Posted May 9, 2018

Share this news article...
Share on LinkedIn
Linkedin
Share on Facebook
Facebook
Tweet about this on Twitter
Twitter
Email this to someone
email

MORE or "UNCATEGORIZED"


Khiron Announces Closing of $28.75 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option

Khiron Life Sciences Corp. (TSX-V:KHRN) (OTCQB:KHRNF), a cannabis... READ MORE

May 28, 2019

Harborside Closes C$19.65 Million Financing

FLRish Inc. d/b/a/ Harborside, a California corporation which man... READ MORE

May 28, 2019

TerrAscend Announces Closing on $69 Million Non-Brokered Private Placement

TerrAscend Corp. (CSE:TER) (OTCQX:TRSSF) has completed its previo... READ MORE

May 28, 2019

Construction of a hydroelectric generating station for the energy transition in the Inukjuak off-grid system

Innergex Renewable Energy Inc. (TSX: INE) the Pituvik Landholding... READ MORE

May 27, 2019

C21 Investments completes acquisition of Swell Companies

C21 Investments Inc. (CSE: CXXI) (OTC: CXXIF) today announced tha... READ MORE

May 27, 2019

Copyright 2025 The Venture Report